Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $8.1 million.

  • Corvus Pharmaceuticals' Total Current Liabilities fell 82.60% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 82.60%. This contributed to the annual value of $35.4 million for FY2024, which is 415.39% up from last year.
  • Corvus Pharmaceuticals' Total Current Liabilities amounted to $8.1 million in Q3 2025, which was down 5.07% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Total Current Liabilities ranged from a high of $46.4 million in Q3 2024 and a low of $6.7 million during Q1 2024.
  • Its 3-year average for Total Current Liabilities is $14.4 million, with a median of $8.3 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 535.79% in 2024, then crashed by 82.60% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $10.8 million in 2022, then plummeted by 36.11% to $6.9 million in 2023, then soared by 415.39% to $35.4 million in 2024, then plummeted by 82.60% to $8.1 million in 2025.
  • Its Total Current Liabilities was $8.1 million in Q3 2025, compared to $8.5 million in Q2 2025 and $9.3 million in Q1 2025.